Use of Anti-CD26 Antibody Levels as Autoimmune and/or Inflammatory Disease Biomarkers

PATENT
P201630620
Priority Date: 2016/05/12
Owners: Universidade of Santiago de Compostela (USC) and Servizo Galego de Saúde (SERGAS)
Inventors: Oscar Cordero Santamaría, Jose María Pego Reigosa and Ruben Varela Calviño

BACKGROUND
Rheumatoid arthritis (RA) is considered an autoimmune and inflammatory disease. It is the most common form of chronic inflammatory joint disease and affects 1-2% of the general population. The diagnosis of RA is still based on specific parameters such as the number of joints affected or the duration of symptoms. However, the early clinical presentation of RA is indistinguishable from others forms of arthritis. While, in recent years, there has been progress in the discovery of molecular and serological markers related to RA, there is still an on-going need for improved methods in early detection, accurate diagnosis, classification, study of the progression and/or prognosis of RA and related autoimmune and inflammatory diseases.

ACHIEVEMENTS AND RESULTS
In vitro method to detect a new biomarker for the screening, diagnosis, and/or monitoring of early or very early detection of RA, and for precision medicine.

Our data suggest:
- a) A specific relation between anti-CD26 auto-antibodies with joints and disease activity.
- b) That antibody levels are affected differently by each therapy (or response).
- c) That antibody levels provide different information compared to the most frequent disease activity parameters used at present (ESR, CRP, platelet count, Hb levels or haematocrit).
- d) That higher anti–CD26 antibody titers are detected in smokers.

PURPOSES AND ADVANTAGES
- A kit for screening, diagnosis, and follow-up of Rheumatoid Arthritis.
- In-house ELISA validated in a cohort of RA patients undergoing different biological a non-biological therapies.
- Potential in prognosis and to outline responders to biological therapies (precision medicine) and in other inflammatory diseases.
- Anti-CD26 antibodies are not ACPA.

COLLABORATION OFFER
Any offer that could extend the patent. This offer can be materialized in a “Partnership Agreement” in order to co-develop this technology, or in a “License Agreement” if you wish to use this patent directly. If you are interested in this offer or need more information about our technology, please contact us.

CONTACT INFORMATION:
Nerea Alonso Sousa
Innovation & Technology Transfer Unit
Fundación Biomédica - IIS Galicia Sur
Tel: +34 986 217454
E-mail: nerea.alonso.sousa@sergas.es
Webs: www.fundacionbiomedica.org
www.iisgaliciasur.es

Montserrat Camiña Tato
Innovation and Technology Transfer Office
Universidade de Santiago de Compostela
Tel: +34 881 815541
E-mail: montserrat.camina@usc.es
Web: www.usc.es

* leaflet funded by the BioCAPS Project (EU FP7/REGPOT-2012-2013-1, GA n° 316265)